Deutsche Bank raises Spyre Therapeutics target to $135

0 min read Updated on 23 Jun 2026, 09:15 PM

Reviewed by

Radhika SScanX News Team

AI Summary

Deutsche Bank analyst David Hoang maintained a Buy rating on Spyre Therapeutics (NASDAQ: SYRE) and raised the price target to $135 from $115.

*this image is generated using AI for illustrative purposes only.

Deutsche Bank analyst David Hoang has maintained a Buy rating on Spyre Therapeutics (NASDAQ: SYRE) and increased the price target to $135 from $115. The adjustment reflects a revised outlook on the company's valuation potential.

Rating and Price Target

The firm's endorsement underscores confidence in Spyre Therapeutics' market position. The new price target of $135 represents an increase over the previous target of $115.

Metric	Value
Rating	Buy
Previous Price Target	$115
New Price Target	$135

What specific factors drove the upward revision of Spyre Therapeutics' valuation potential?

How might this price target increase influence investor sentiment and trading volume in the short term?

What upcoming clinical milestones or product developments could further impact Spyre's stock performance?

Read Next Article

Spyre reports positive Phase 2 data for SPY002 in ulcerative colitis

1 min read Updated on 15 Jun 2026, 06:53 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

AI Summary

Spyre Therapeutics announced positive 12-week induction data from Part A of the Phase 2 SKYLINE trial for SPY002 in ulcerative colitis patients. The therapy met its primary endpoint with a significant reduction in RHI score and showed a consistent safety profile.

*this image is generated using AI for illustrative purposes only.

Spyre Therapeutics, Inc. (NASDAQ: SYRE) announced positive 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY002, a potential best-in-class anti-TL1A therapy for moderately-to-severely active ulcerative colitis (UC). The treatment met its primary endpoint with a statistically significant reduction of 10.7 points (p<0.0001) from baseline at Week 12 in Robart's Histopathology Index (RHI) score, demonstrating a consistent safety profile. These results mark a significant step forward for the clinical-stage biotechnology company focused on advancing immunology treatments.

The Phase 2 SKYLINE trial evaluated SPY002 over a 12-week induction period. Spyre Therapeutics reported that the therapy was well tolerated, with safety data aligning with expectations. The company aims to deliver more complete disease control, greater durability, and a simpler treatment experience for patients through its next-generation therapies.

Key Trial Details

Parameter	Details
Trial Name	SKYLINE
Phase	Phase 2
Treatment	SPY002
Indication	Moderately-to-severely active ulcerative colitis
Induction Period	12 weeks
Primary Endpoint	Met
Safety Profile	Consistent, well tolerated

SPY002 is being investigated as a potential best-in-class anti-TL1A treatment. The positive results from Part A of the trial support its continued development for ulcerative colitis, a chronic inflammatory bowel disease. Spyre Therapeutics is committed to developing therapies that elevate the standard in immunology by addressing unmet needs in chronic inflammatory conditions through innovative treatment approaches.

What are the next steps for SPY002 following the positive Part A data, and when will Part B of the SKYLINE trial commence?

How might these results influence Spyre Therapeutics' partnerships or collaborations with larger pharmaceutical companies?

What competitive advantages does SPY002 have over other anti-TL1A therapies currently in development for ulcerative colitis?